MeSH term
Frequency | Condition_Probility | Antibodies, Monoclonal/chemistry | 2 | 2.0 |
Humans | 346 | 0.0 |
Immunohistochemistry | 57 | 0.0 |
Prognosis | 19 | 0.0 |
Recurrence | 2 | 0.0 |
Time Factors | 14 | 0.0 |
Acute Disease | 6 | 0.0 |
Adult | 95 | 0.0 |
Base Sequence | 27 | 0.0 |
DNA, Neoplasm/genetics | 9 | 1.0 |
Female | 123 | 0.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
Male | 123 | 0.0 |
Middle Aged | 92 | 0.0 |
Molecular Sequence Data | 38 | 0.0 |
*Mutation | 23 | 0.0 |
Proto-Oncogene Proteins/*genetics | 8 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 6 | 1.0 |
Research Support, Non-U.S. Gov't | 146 | 0.0 |
Adolescent | 31 | 0.0 |
Proto-Oncogene Protein c-kit/*genetics | 24 | 58.0 |
Amino Acid Sequence | 32 | 0.0 |
DNA Mutational Analysis | 25 | 0.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
*Mutation, Missense | 4 | 0.0 |
Phosphorylation | 26 | 0.0 |
Tumor Cells, Cultured | 14 | 0.0 |
Aged | 68 | 0.0 |
Case-Control Studies | 5 | 0.0 |
Proto-Oncogene Protein c-kit/*analysis | 9 | 36.0 |
*Chromosome Aberrations | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Karyotyping | 4 | 0.0 |
Signal Transduction | 6 | 0.0 |
Stromal Cells/metabolism/pathology | 4 | 8.0 |
Antineoplastic Agents/therapeutic use | 4 | 1.0 |
Gastrointestinal Neoplasms/*diagnosis/drug therapy/metabolism | 2 | 100.0 |
Mutation | 35 | 0.0 |
Piperazines/therapeutic use | 5 | 26.0 |
Proto-Oncogene Protein c-kit/genetics/metabolism | 7 | 70.0 |
Pyrimidines/therapeutic use | 5 | 22.0 |
Stromal Cells/pathology | 12 | 21.0 |
Tumor Markers, Biological/metabolism | 6 | 1.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 7 | 3.0 |
English Abstract | 19 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 11 | 0.0 |
Reagent Kits, Diagnostic/*standards | 3 | 13.0 |
Reproducibility of Results | 14 | 0.0 |
Dental Enamel Proteins/*genetics | 2 | 11.0 |
Forensic Medicine/*methods | 2 | 6.0 |
Pregnancy | 5 | 0.0 |
Prenatal Diagnosis/*methods | 2 | 1.0 |
Exons/*genetics | 3 | 0.0 |
Gastrointestinal Neoplasms/chemistry/*genetics/pathology | 2 | 66.0 |
Polymerase Chain Reaction/methods | 7 | 0.0 |
*Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Proto-Oncogene Protein c-kit/analysis/*genetics | 7 | 87.0 |
Sensitivity and Specificity | 35 | 1.0 |
Stromal Cells/chemistry/pathology | 2 | 9.0 |
Cholesterol/blood | 2 | 0.0 |
Risk Factors | 4 | 0.0 |
Sex Factors | 2 | 0.0 |
Retrospective Studies | 9 | 0.0 |
Vimentin/metabolism | 2 | 1.0 |
Animals | 80 | 0.0 |
Blotting, Northern | 2 | 0.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Down-Regulation | 4 | 0.0 |
Mice | 42 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 48 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 15 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
*Blood Donors | 2 | 1.0 |
*DNA Fingerprinting | 5 | 11.0 |
Electrophoresis, Capillary | 3 | 6.0 |
Polymerase Chain Reaction | 33 | 0.0 |
Quality Control | 4 | 2.0 |
Alleles | 16 | 0.0 |
Gene Frequency | 4 | 0.0 |
Genetics, Population | 4 | 1.0 |
Regression Analysis | 2 | 0.0 |
Tandem Repeat Sequences/*genetics | 8 | 8.0 |
Cells, Cultured | 6 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Phenotype | 5 | 0.0 |
Stem Cell Factor/physiology | 3 | 23.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Pyrimidines/pharmacology | 6 | 5.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 19 | 0.0 |
Antineoplastic Agents/*therapeutic use | 7 | 1.0 |
Piperazines/*therapeutic use | 9 | 19.0 |
Pyrimidines/*therapeutic use | 9 | 20.0 |
Diagnosis, Differential | 11 | 0.0 |
Predictive Value of Tests | 5 | 0.0 |
Proto-Oncogene Protein c-kit/*analysis/*metabolism | 2 | 100.0 |
Child | 29 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Actins/analysis | 2 | 1.0 |
Aged, 80 and over | 34 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Follow-Up Studies | 6 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Proto-Oncogene Protein c-kit/genetics | 9 | 25.0 |
S100 Proteins/analysis | 3 | 1.0 |
Apoptosis | 3 | 0.0 |
Blotting, Western | 6 | 0.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Proto-Oncogene Protein c-kit/genetics/*metabolism | 4 | 36.0 |
Rats | 9 | 0.0 |
Antineoplastic Agents/adverse effects/*therapeutic use | 2 | 6.0 |
Clinical Trials | 3 | 0.0 |
Piperazines/adverse effects/*therapeutic use | 2 | 66.0 |
Pyrimidines/adverse effects/*therapeutic use | 2 | 66.0 |
*Stromal Cells | 2 | 33.0 |
Treatment Outcome | 8 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Binding Sites | 5 | 0.0 |
Comparative Study | 59 | 0.0 |
In Vitro | 2 | 0.0 |
Piperazines/*pharmacology | 5 | 8.0 |
Protein Kinase Inhibitors/*pharmacology | 3 | 42.0 |
Pyrimidines/*pharmacology | 5 | 7.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
*Reagent Kits, Diagnostic | 18 | 31.0 |
Databases, Factual | 2 | 0.0 |
*Forensic Medicine | 2 | 4.0 |
*Genetics, Population | 12 | 3.0 |
*Tandem Repeat Sequences | 16 | 14.0 |
United States | 5 | 0.0 |
DNA Fingerprinting/*methods | 8 | 15.0 |
Polymerase Chain Reaction/*methods | 9 | 1.0 |
Immunoenzyme Techniques | 22 | 0.0 |
Proto-Oncogene Protein c-kit/*metabolism | 17 | 36.0 |
*Alleles | 4 | 0.0 |
Software | 2 | 0.0 |
DNA Primers | 7 | 0.0 |
Genotype | 9 | 0.0 |
DNA, Complementary/genetics | 4 | 0.0 |
Enzyme Activation | 9 | 0.0 |
Stromal Cells/enzymology/pathology | 2 | 33.0 |
Antigens, CD34/analysis | 9 | 1.0 |
Germ-Line Mutation | 2 | 0.0 |
Gastrointestinal Neoplasms/chemistry/*pathology | 2 | 25.0 |
Proto-Oncogene Protein c-kit/analysis | 6 | 12.0 |
Enzyme Inhibitors/*therapeutic use | 3 | 3.0 |
Gastrointestinal Neoplasms/*drug therapy/pathology | 2 | 66.0 |
Radioimmunoassay | 7 | 0.0 |
DNA/genetics | 3 | 0.0 |
Poland | 6 | 4.0 |
Disease Progression | 6 | 0.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Exons | 12 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Chickens | 2 | 0.0 |
Proto-Oncogene Protein c-kit/metabolism | 8 | 16.0 |
Signal Transduction/physiology | 3 | 0.0 |
Biopsy, Needle | 3 | 0.0 |
Gene Deletion | 2 | 0.0 |
Point Mutation | 8 | 0.0 |
Stomach Neoplasms/genetics/metabolism/*pathology | 2 | 28.0 |
European Continental Ancestry Group | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
DNA, Neoplasm/analysis | 8 | 1.0 |
Immunophenotyping | 5 | 0.0 |
Recombinant Proteins/pharmacology | 3 | 0.0 |
Stem Cell Factor/pharmacology | 5 | 3.0 |
Antigens, CD34/*analysis | 2 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 7 | 0.0 |
Gastrointestinal Neoplasms/*genetics/metabolism | 2 | 50.0 |
Proto-Oncogene Protein c-kit/*genetics/metabolism | 12 | 75.0 |
Biological Markers/blood | 2 | 0.0 |
Child, Preschool | 17 | 0.0 |
Infant | 11 | 0.0 |
Infant, Newborn | 6 | 0.0 |
Oncogene Proteins/*blood | 2 | 66.0 |
Solubility | 4 | 0.0 |
Stem Cell Factor/*blood | 2 | 66.0 |
Antigens, CD/analysis | 3 | 0.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Fatal Outcome | 4 | 0.0 |
*Immunohistochemistry | 2 | 2.0 |
Remission Induction | 2 | 0.0 |
Serine Endopeptidases/analysis | 2 | 5.0 |
Cell Line | 13 | 0.0 |
Mast Cells/metabolism | 3 | 11.0 |
Phosphorylation/drug effects | 3 | 0.0 |
Protein Binding | 3 | 0.0 |
*Signal Transduction | 3 | 0.0 |
src Homology Domains | 3 | 0.0 |
Tandem Repeat Sequences | 3 | 2.0 |
*Mast Cells | 2 | 100.0 |
Stromal Cells | 2 | 5.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Forensic Medicine | 3 | 5.0 |
*Gene Frequency | 10 | 1.0 |
Austria | 2 | 3.0 |
European Continental Ancestry Group/genetics | 4 | 0.0 |
Likelihood Functions | 3 | 1.0 |
Reagent Kits, Diagnostic | 16 | 10.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
DNA Fingerprinting/instrumentation/methods | 2 | 33.0 |
Discriminant Analysis | 2 | 2.0 |
Gene Frequency/*genetics | 4 | 2.0 |
Heterozygote | 3 | 0.0 |
Minisatellite Repeats/*genetics | 2 | 2.0 |
Polymerase Chain Reaction/instrumentation/methods | 2 | 33.0 |
Paternity | 2 | 2.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Age Factors | 5 | 0.0 |
Reference Standards | 3 | 1.0 |
*Point Mutation | 6 | 0.0 |
*Proto-Oncogenes | 7 | 1.0 |
Antigens, Bacterial/*immunology | 3 | 2.0 |
Cross Reactions | 2 | 0.0 |
Immunoblotting | 4 | 0.0 |
Receptor, Epidermal Growth Factor/*metabolism | 2 | 0.0 |
S100 Proteins/metabolism | 3 | 2.0 |
Hamsters | 3 | 0.0 |
Gastrointestinal Neoplasms/*genetics/metabolism/pathology | 2 | 28.0 |
Survival Rate | 5 | 0.0 |
Antibodies/immunology | 2 | 0.0 |
Gastrointestinal Neoplasms/*diagnosis/metabolism | 2 | 100.0 |
Staining and Labeling | 2 | 0.0 |
Stromal Cells/metabolism/*pathology | 3 | 25.0 |
Linear Models | 2 | 0.0 |
DNA, Bacterial/analysis | 2 | 3.0 |
Species Specificity | 6 | 0.0 |
Evaluation Studies | 13 | 1.0 |
Blotting, Southern | 5 | 0.0 |
Dogs | 5 | 0.0 |
Pedigree | 7 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Gastrointestinal Neoplasms/*metabolism/pathology | 5 | 33.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Isoenzymes/*metabolism | 2 | 0.0 |
Receptor, Platelet-Derived Growth Factor alpha/*genetics/metabolism | 2 | 66.0 |
Stromal Cells/*metabolism/pathology | 4 | 50.0 |
Prospective Studies | 4 | 0.0 |
*Latex Fixation Tests | 2 | 25.0 |
Stromal Cells/chemistry/*pathology | 3 | 27.0 |
Tumor Markers, Biological/analysis | 9 | 1.0 |
Risk Assessment | 2 | 0.0 |
Antigens, CD34/*metabolism | 3 | 2.0 |
Cell Division | 7 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 5 | 0.0 |
Genes, Dominant | 4 | 0.0 |
Stem Cell Factor/metabolism | 4 | 17.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Dimerization | 5 | 0.0 |
Models, Biological | 3 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Tumor Markers, Biological | 4 | 0.0 |
Biopsy | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Cell Separation | 2 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Hematopoietic Stem Cell Transplantation | 2 | 1.0 |
Transplantation, Heterologous | 4 | 0.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Colony-Forming Units Assay | 4 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Piperazines/pharmacology | 4 | 3.0 |
Transplantation, Homologous | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 5 | 2.0 |
Gastrointestinal Neoplasms/*genetics/pathology | 3 | 17.0 |
Mice, Nude | 6 | 0.0 |
Mutation/*genetics | 5 | 0.0 |
Stromal Cells/drug effects/pathology | 2 | 40.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Antigens, CD34/metabolism | 3 | 1.0 |
Desmin/metabolism | 2 | 8.0 |
DNA Primers/chemistry | 4 | 0.0 |
Tyrosine/metabolism | 5 | 0.0 |
Estrogens, Catechol/*urine | 2 | 100.0 |
Freezing | 2 | 2.0 |
Hydroxyestrones/*urine | 2 | 50.0 |
Population Surveillance | 2 | 1.0 |
Probability | 2 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Survival Analysis | 3 | 0.0 |
Mutation, Missense | 3 | 0.0 |
Gastrointestinal Neoplasms/*enzymology | 2 | 50.0 |
Gene Expression Regulation | 2 | 0.0 |
Isoenzymes/*biosynthesis | 2 | 3.0 |
Oligonucleotide Array Sequence Analysis | 5 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Proto-Oncogene Protein c-kit/biosynthesis | 3 | 20.0 |
Receptor, Platelet-Derived Growth Factor alpha/*genetics | 5 | 45.0 |
Liver Transplantation | 3 | 5.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Proto-Oncogene Protein c-kit/*biosynthesis/genetics | 3 | 42.0 |
Proto-Oncogene Protein c-kit/*biosynthesis | 3 | 27.0 |
Reagent Kits, Diagnostic/standards | 2 | 12.0 |
*Radioimmunoassay | 2 | 5.0 |
Reference Values | 7 | 0.0 |
Saliva/*chemistry | 2 | 5.0 |
COS Cells | 4 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Transfection | 10 | 0.0 |
Exons/genetics | 4 | 0.0 |
DNA Probes | 4 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Tumor Markers, Biological/*metabolism | 3 | 0.0 |
Ligands | 5 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Bone Marrow/pathology | 2 | 0.0 |
Gastrointestinal Neoplasms/*genetics | 8 | 24.0 |
Cell Line, Tumor | 4 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
*Germ-Line Mutation | 2 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Gene Expression Regulation, Leukemic/*genetics | 2 | 20.0 |
Receptors, Platelet-Derived Growth Factor/*genetics | 2 | 18.0 |
Stomach Neoplasms/*genetics/pathology | 2 | 4.0 |
Biological Markers | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Bacteriological Techniques | 2 | 8.0 |
Signal Transduction/drug effects | 3 | 0.0 |
Oxalates/*urine | 3 | 75.0 |
Restriction Mapping | 2 | 0.0 |
Kidney Transplantation | 2 | 1.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Fetus/metabolism | 2 | 1.0 |
DNA Fingerprinting/methods | 5 | 7.0 |
Turkey | 4 | 2.0 |
Proto-Oncogene Protein c-kit/*analysis/genetics | 2 | 40.0 |
Cell Division/drug effects | 6 | 0.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
*Immunoenzyme Techniques | 2 | 1.0 |
Structure-Activity Relationship | 2 | 0.0 |
Drug Stability | 3 | 1.0 |
Signal Transduction/*genetics | 2 | 1.0 |
False Negative Reactions | 3 | 2.0 |
Virology/*methods/statistics & numerical data | 2 | 40.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 3 | 0.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 4 | 2.0 |
Epidemiologic Methods | 2 | 3.0 |
Feasibility Studies | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Interleukin-3/pharmacology | 3 | 1.0 |
Proto-Oncogene Protein c-kit/*physiology | 2 | 40.0 |
HIV-1/*immunology | 2 | 0.0 |
Gestational Age | 2 | 0.0 |
Immunoassay | 3 | 1.0 |
Antineoplastic Agents/pharmacology | 3 | 0.0 |
Stromal Cells/*pathology | 3 | 10.0 |
*Gene Amplification | 2 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Proto-Oncogene Protein c-kit | 16 | 20.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Stem Cell Factor | 5 | 5.0 |
Gastrointestinal Neoplasms/*metabolism | 2 | 15.0 |
Gene Expression | 3 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 2 | 1.0 |
Receptors, Colony-Stimulating Factor/genetics/*metabolism | 2 | 100.0 |
Kinetics | 2 | 0.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors | 2 | 4.0 |
Indicators and Reagents | 2 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
*Chromosomes, Human, Pair 4 | 5 | 2.0 |
*Chromosome Banding | 2 | 8.0 |
*Chromosome Mapping | 2 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Genes, Structural | 2 | 0.0 |
Piebaldism/*genetics | 5 | 55.0 |
Calibration | 3 | 2.0 |
Technetium Tc 99m Exametazime | 2 | 28.0 |
Multigene Family | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics | 3 | 2.0 |
Receptors, Colony-Stimulating Factor/*genetics | 3 | 27.0 |
Taiwan | 2 | 1.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Frameshift Mutation | 2 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Macrophages/metabolism | 2 | 0.0 |
Receptors, Platelet-Derived Growth Factor | 2 | 6.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
Receptors, Cell Surface/*genetics | 2 | 0.0 |
Blood Donors | 2 | 0.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Tandem Repeat Sequences/genetics | 2 | 4.0 |
Swine | 2 | 0.0 |
Forensic Medicine/methods | 3 | 8.0 |
Leukemia, Myeloid, Chronic/*drug therapy | 2 | 20.0 |
Proto-Oncogene Protein c-kit/drug effects/genetics | 2 | 100.0 |
Antibody Specificity | 2 | 0.0 |
Protein p53/metabolism | 2 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
Chromosomes, Human, Pair 14/genetics | 2 | 2.0 |
Methods | 2 | 0.0 |
Indoles/*pharmacology | 2 | 2.0 |
Pyrroles/*pharmacology | 2 | 4.0 |
Chronic Disease | 2 | 0.0 |
Gene Targeting | 2 | 0.0 |
Oncogene Proteins/analysis/biosynthesis | 2 | 100.0 |
Translocation, Genetic | 2 | 0.0 |
Leukocyte Count | 2 | 0.0 |
Immunohistochemistry/*methods/standards | 2 | 40.0 |
Vimentin/analysis | 2 | 0.0 |
Codon/genetics | 2 | 0.0 |
Genetics, Population/*statistics & numerical data | 2 | 50.0 |
